'Triple-Therapy' Study With TGR-1202 + TG-1101... - CLL Support
'Triple-Therapy' Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced CLL
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
Off ibrutinib x 2 weeks, a novel ultra low dose triple therapy for CLL and Richter's and CLL Society recognized for its reliable robust info
How about no COVID-19 news in a post:
I updated my blog with good news at...
Clemastine (Tavegyl), an over-the-counter drug, found to be effective at inducing LMP and cell death
For what it may be worth, thougbt some of you might like to see this:
"Lysosomes in chronic...
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lym
Background: Current therapies for CLL/SLL have frequent toxicities, are non-curative, and several...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Related Posts
- YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success
- Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL
- T-cell /Cellular Immune Responses in Patients with CLL from the Pfizer-BioNTech COVID-19 Vaccine (BNT162b mRNA Covid19 Vaccine)
- Zanubrutinib-Gazyva Shows Promise for CLL/SLL
- BTK Degrader Shows Potential for Treating Refractory CLL and SLL
